Product Datasheet: GWB-B784BE - Mycoplasma pneumoniae IgG - Genway Biotech
 
Mycoplasma pneumoniae IgG
Data Sheet
 
Product Number GWB-B784BE
Product Page www.genwaybio.com/mycoplasma-pneumoniae-igg-elisa-2739
Name Mycoplasma pneumoniae IgG
Size 96 Wells
Related Product Names (Synonyms) Mycoplasma pneumoniae IgG - ELISA
Molecular Weight 0.5
Storage The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.
GenWay Legacy Database ID 475108
Intended Use Research Use Only
Availability Available
Description Please click here for MSDS PDF Datasheet

Product Name: Mycoplasma pneumoniae IgG - ELISA

# of Samples: 1 x 96 Assays

Intended Use: The M. pneumoniae IgG-ELISA is intended for the qualitative determination of IgG class antibodies against M. pneumoniae in human serum or plasma (citrate).

Introduction: The mycoplasms belong to the class Mollicutes comprising three distinct families and four genera, one of which is Mycoplasma with over 60 species. Mycoplasms are the smallest free living organisms known (300 to 500 nm in diameter) and unlike regular bacteria they lack a cell wall. Mycoplasms are extracellular parasites, especially on mucous membranes, which can cause infections in human, animals, plants, and cell cultures. Mycoplasma pneumoniae is primarily a respiratory pathogen (obligat) in human involving the nasopharynx, throat, trachea, bronchi, bronchioles, and alveoli. Other Mycoplasms, M. buccale, M. faucium, M. orale and M. salivarium are commensals in the oral cavity. Mycoplasma hominis and Ureaplasma urealyticum inhabit primarily the genital tract and may act as opportunistic invaders. M. pneumoniae is by far the most important pathogen of this group. Infection with M. pneumoniae occurs worldwide, its epidemiology has been studied primarily in the USA, Europe, and Japan. Infections are endemic in larger urban areas, and epidemic increases are observed at varying intervalls. M. pneumoniae has been estimated to cause 15-20% of all pneumoniae; the rate is highest in children and young adults. 74% of infections with M. pneumoniae are asymptomatic, reinfection may occur. Naturally acquired immunity to infection with M. pneumoniae appears to be of limited duration (2-3 years).
Infection may be identified by:
Microscopy
Hemadsorption, Tetrazolium reduction (specific for M. pneumoniae), Complement fixation
Detection of antibody production by ELISA Serology: complement fixation (CF), neutralization (N) and hemagglutination-inhibition (HAI); Detection of antibodies and the hexon antigen by ELISA.

Principles of the assay: The qualitative immunoenzymatic determination of IgG-class antibodies against M. pneumoniae is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.
Microtiter strip wells are precoated with M. pneumoniae antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgG conjugate is added. This conjugate binds to the captured M. pneumoniae-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of M. pneumoniae-specific IgG antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader

Storage and Stability: The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.

Limitations of the Test: Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data.
In immunocompromised patients and newborns serological data only have restricted value.

References Clyde WA Jr:Clinical overviwe of typical M. pneumoniae infections.Clin.Infect.Dis 1993 Aug;17 Suppl 1:S32-6 MedlineE.Jacobs.1993.Serologicals Diagnosis of M. peumoniae Infections:Current Prodedures.Clinical Infectious Diseases.17(suppl 1) 79-82Foy,H.M.1993.Infections caused by M. pneumoniae and possible populations of patients.Clinical Infectious Diseases.17 (suppl 1) 37-46Handley J.G.,andL.D.Gray.1997.The incidence of M. pneumoniae Board Family Practice 11(6):425-429Vikerfors,T.,Brodin,G.,Grandien,M.,Hirshberg,L.,Krook,A.,andC.A.Petterssonspecific IgM antibodies for the diagnosis of M. pneumoniae infections Scand.J.Infect.Dis.20(6):601-610Wiegand,R.:M.pneumoniae.In:Brandis,H.,W.Köhler,H.J.Eggers,G.Pulverer(ed.):Med. Mikrobiologie 1994.Gustav Fischer Verlag Stuttgart,Jena,New York (1994) 767-769
 

GENWAY BIOTECH manufactures and sells quality antibody products covering genome wide proteins.

GENWAY BIOTECH
6777 Nancy Ridge Drive San Diego, CA 92121 USA | Tel: (858)458-0866 | sales@genwaybio.com